Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery

Abstract

Purpose: To evaluate the prevalence of dry eye disease (DED) after cataract surgery, and the impact of hyaluronic acid and ginkgo biloba eyedrops (HA-GB). Methods: Forty patients with no DED received Ocular Surface Disease Index (OSDI) questionnaire, assessment of conjunctival hyperemia and epithelial damage, fluorescein tear break-up time (TBUT) at baseline, day 1, week 1, and 4; adherence and tolerability were checked at weeks 1 and 4. At day 0 patients underwent cataract surgery and were randomized to standard postoperative care (control group) or standard postoperative care + HA-GB 3 times a day for 4 weeks (HA-GB group). Results: At baseline, TBUT was 9.6 ± 2.6 sec in controls and 9.0 ± 1.6 in HA-GB; thereafter it was higher in HA-GB group: 5.8 ± 2.3 versus 7.8 ± 3.2 (week 1, P = 0.03) and 6.4 ± 2.3 versus 8.5 ± 2.5 (week 4, P = 0.009). OSDI and conjunctival hyperemia were better in HA-GB group at week 4; respectively, 9.0 ± 5.7 versus 14.8 ± 7.3 ( P = 0.004) and 5% versus 35% ( P = 0.04). In the last 2 visits 50% of controls were symptomatic (OSDI of 13 or higher) compared with 16% on HA-GB group ( P < 0.001). In addition, tolerability was higher in HA-GB group (week 1: 0.81 ± 0.20 versus 0.70 ± 0.24, P = 0.007; week 4: 0.93 ± 0.17 versus 0.80 ± 0.28, P = 0.001). Conclusion: Treatment with HA-GB is effective in reducing DED signs and symptoms in patients receiving cataract surgery, with high tolerability and safety profiles. (ID number NCT05002036).

Hyaluronic Acid and Galacto-Xyloglucan Eyedrop Efficacy in Young-Adult Oral Contraceptive Users of Childbearing Age

“…In a longitudinal approach, our results showed a statistically significant decrease in OSDI scores in the HA-GX group after six weeks of treatment. This trend corresponds to that shown by several studies using the same tear (HA-GX) to assess dry eye symptoms [ 27 , 28 , 43 , 45 ]. Other studies have also shown a decrease in the OSDI score when using tears that combine HA with other molecules [ 43 , 44 , 45 , 46 , 47 , 48 ].…”

“…This trend corresponds to that shown by several studies using the same tear (HA-GX) to assess dry eye symptoms [ 27 , 28 , 43 , 45 ]. Other studies have also shown a decrease in the OSDI score when using tears that combine HA with other molecules [ 43 , 44 , 45 , 46 , 47 , 48 ]. The SPEED score also showed a statistically significant improvement at the end of the study in the HA-GX group.…”

Update on Dry Eye Disease Treatment: Evidence From Randomized Controlled Trials

“…Artificial tear drops are widely used among both healthy individuals and in DED patients (Table 1). 9–33 New products, in the form of osmoprotectants, lipid-based formulations, hyaluronic acid preparations/combinations, and multicomponent AT preparations, have emerged into the market. Despite a number of new studies comparing different AT formulations, it is hard to make comparisons between preparations because of variable patient populations tested and variable endpoints.…”

“…Currently, there seems to be no evidence of superiority of a particular AT formulation over another or better efficacy of any multicomponent AT formulation over a basic one-component AT formulation in a particular subset of patients with DED (Table 1). 9–33…”

“…Past few years have witnessed developments of new molecules or ideas for the management of several forms of DED, with promising results, such as the use of lubricin, 11 taurine, 15 perfluorohexyloctane 100% (PFHO, NovaTears, Novaliq, Germany), 22 xanthan gum, 23 and gingko biloba. 33…”